Analysts Offer Predictions for Teladoc Health Q3 Earnings

Teladoc Health, Inc. (NYSE:TDOC) – Equities researchers at Zacks Research lowered their Q3 2026 EPS estimates for Teladoc Health in a report issued on Wednesday, August 19th. Zacks Research analyst Team now anticipates that the health services provider will post earnings per share of ($0.21) for the quarter, down from their prior estimate of ($0.20). The consensus estimate for Teladoc Health’s current full-year earnings is ($0.89) per share. Zacks Research also issued estimates for Teladoc Health’s Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.89) EPS, Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.23) EPS, FY2027 earnings at ($0.98) EPS, Q1 2028 earnings at ($0.14) EPS and Q2 2028 earnings at ($0.21) EPS.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. The company had revenue of $606.93 million during the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS.

A number of other equities analysts have also recently weighed in on TDOC. Canaccord Genuity Group decreased their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Citigroup decreased their price target on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a research report on Monday, August 3rd. Bank of America increased their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Teladoc Health in a report on Wednesday. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.54.

Teladoc Health Stock Down 2.7%

Teladoc Health stock opened at $6.48 on Friday. The firm has a fifty day moving average of $8.10 and a 200-day moving average of $6.59. Teladoc Health has a 52-week low of $4.40 and a 52-week high of $9.89. The firm has a market capitalization of $1.18 billion, a P/E ratio of -6.55 and a beta of 2.12.

Insider Buying and Selling at Teladoc Health

In other news, CEO Charles Divita III sold 19,132 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $145,977.16. Following the transaction, the chief executive officer directly owned 389,894 shares in the company, valued at approximately $2,974,891.22. This trade represents a 4.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $60,322.78. Following the sale, the insider owned 110,261 shares in the company, valued at approximately $841,291.43. This trade represents a 6.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,195 shares of company stock valued at $299,058 over the last three months. 0.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Teladoc Health

A number of hedge funds have recently added to or reduced their stakes in TDOC. Allworth Financial LP bought a new position in shares of Teladoc Health during the second quarter worth about $25,000. Twin Lakes Capital Management LLC acquired a new position in Teladoc Health during the 2nd quarter valued at about $26,000. IFP Advisors Inc boosted its stake in Teladoc Health by 412.1% during the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 3,210 shares during the period. EFG International AG bought a new position in Teladoc Health in the 2nd quarter worth about $35,000. Finally, PNC Financial Services Group Inc. increased its stake in shares of Teladoc Health by 177.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 2,810 shares during the period. 76.82% of the stock is currently owned by institutional investors.

Trending Headlines about Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Improved full-year earnings outlook: Zacks Research raised its FY2026 EPS forecast to a loss of $0.89 from $0.96 and its FY2027 forecast to a loss of $0.98 from $1.04. Estimates for Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027 and Q1 2028 also improved modestly. The revisions suggest somewhat better expected cost control or operating performance, although Teladoc is still projected to remain unprofitable. Teladoc Health analyst estimates
• Neutral Sentiment: Near-term estimates remain broadly unchanged: Zacks maintained its full-year 2026 loss estimate at $0.89 per share, in line with consensus. Teladoc’s stock opened at $6.48, below its 50-day moving average of $8.10 and close to its 200-day average of $6.59, reflecting continued investor caution around the company’s profitability and growth prospects.
• Negative Sentiment: Some quarterly forecasts worsened: Zacks reduced its Q3 2026 EPS forecast to a loss of $0.21 from $0.20 and lowered its Q2 2028 estimate to a loss of $0.21 from $0.20. These changes point to continued uncertainty about the pace of earnings improvement.
• Negative Sentiment: Investor investigation announced: Pomerantz LLP said it is investigating potential claims on behalf of Teladoc investors. Although the announcement does not establish wrongdoing, such investigations can increase legal and reputational concerns and weigh on sentiment. Pomerantz investor alert

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.